IN2012DN00546A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00546A
IN2012DN00546A IN546DEN2012A IN2012DN00546A IN 2012DN00546 A IN2012DN00546 A IN 2012DN00546A IN 546DEN2012 A IN546DEN2012 A IN 546DEN2012A IN 2012DN00546 A IN2012DN00546 A IN 2012DN00546A
Authority
IN
India
Prior art keywords
derivatives
pharmaceutical compositions
tazarotene
making
subject matter
Prior art date
Application number
Inventor
Ge Xue
Wong Hansen
Huang Chern Wendy
Hofland Hans
j bishop Michael
Frank Cai Xin
Colborn Alan
Original Assignee
Stiefel Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Laboratories filed Critical Stiefel Laboratories
Publication of IN2012DN00546A publication Critical patent/IN2012DN00546A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The presently described subject matter relates to new derivatives of tazarotene that also exhibit retinoid activity, pharmaceutical compositions comprising the derivatives, method of treating skin disorders with the pharmaceutical compositions, and process of making the derivatives.
IN546DEN2012 2009-07-16 2010-07-16 IN2012DN00546A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21379409P 2009-07-16 2009-07-16
US27225709P 2009-09-04 2009-09-04
PCT/US2010/042225 WO2011009023A1 (en) 2009-07-16 2010-07-16 Tazarotene derivatives

Publications (1)

Publication Number Publication Date
IN2012DN00546A true IN2012DN00546A (en) 2015-06-12

Family

ID=43449815

Family Applications (1)

Application Number Title Priority Date Filing Date
IN546DEN2012 IN2012DN00546A (en) 2009-07-16 2010-07-16

Country Status (16)

Country Link
US (3) US20120115909A1 (en)
EP (1) EP2453746A4 (en)
JP (1) JP5635090B2 (en)
KR (1) KR101536806B1 (en)
CN (1) CN102595892B (en)
AU (1) AU2010273261B2 (en)
BR (1) BR112012001680A2 (en)
CA (1) CA2768015C (en)
EA (1) EA022322B1 (en)
IL (1) IL217519A (en)
IN (1) IN2012DN00546A (en)
MX (1) MX2012000768A (en)
NZ (1) NZ598240A (en)
SG (1) SG177579A1 (en)
WO (1) WO2011009023A1 (en)
ZA (1) ZA201200253B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105050D0 (en) 2011-03-25 2011-05-11 Iiaa Ltd Pharmaceutical agent
CN111298120A (en) * 2011-06-24 2020-06-19 格里生物公司 Prevention and treatment of inflammatory disorders
CN106918676B (en) * 2015-12-24 2020-08-11 重庆华邦制药有限公司 Method for separating and measuring contents of two drugs in tazarotene betamethasone cream and related substances
CN107176945B (en) * 2016-03-11 2021-06-08 中国科学院上海有机化学研究所 A kind of retinoic acid compound, its preparation method, intermediate and application
WO2017152725A1 (en) * 2016-03-11 2017-09-14 中国科学院上海有机化学研究所 Retinoid compound, preparation method therefor, intermediates thereof and application thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801593A (en) * 1979-09-13 1989-01-31 Burroughs Wellcome Co. Chemotherapeutic agents
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5399561A (en) * 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
HUT63405A (en) 1990-10-09 1993-08-30 Allergan Inc Process for producing acetylene derivatives substituted with chromanyl, thiochromanyl or tetrahydroquinolinyl group and having retinoid-like activity, as well as pharmaceutical compositions comprising same as active ingredient
EP0571546B1 (en) 1991-02-13 1996-10-16 Allergan, Inc. Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity
EP0577737A1 (en) 1991-03-26 1994-01-12 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
AU9259598A (en) * 1997-07-08 1999-02-08 Gist-Brocades B.V. Topical application of a combination of benzoyl peroxide and a second active ingredient
AU5132799A (en) * 1998-07-28 2000-02-21 Bershad, Susan Short contact treatment of acne and photoaging with topical retinoids
US6048902A (en) * 1999-02-12 2000-04-11 Lebwohl; Mark G. Short contact treatment of psoriasis with topical retinoids
FR2830449B1 (en) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique USE OF TAZAROTENE FOR THE PREPARATION OF A NAIL VARNISH FOR THE TREATMENT AND / OR PREVENTION OF PSORIASIS AND A NAIL VARNISH CONTAINING IT
CN1210041C (en) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 Complex external medicine for treating acne
ITMI20050357A1 (en) * 2005-03-08 2006-09-09 Solmag S P A TAZAROTENE PREPARATION PROCEDURE
AR054805A1 (en) * 2005-06-29 2007-07-18 Stiefel Laboratories TOPICAL COMPOSITIONS FOR SKIN TREATMENT
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
MXPA06008988A (en) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala TOPICAS PREPARATIONS ANTIACNE CONTAINING RETINOID (TAZAROTENE OR ADAPALENE), ANTIBIOTIC (CLINDAMYCIN PHOSPHATE) AND / OR CHERATOLYTIC (BONZOIL PEROXIDE IN MICROESPONJAS).
EA200970724A1 (en) * 2007-02-01 2010-02-26 Сол-Джел Текнолоджиз Лтд. COMPOSITIONS FOR LOCAL APPLICATION CONTAINING PEROXIDE AND RETINOID

Also Published As

Publication number Publication date
IL217519A (en) 2015-06-30
IL217519A0 (en) 2012-02-29
CN102595892B (en) 2014-09-10
US20140357669A1 (en) 2014-12-04
US20140357672A1 (en) 2014-12-04
KR20120056821A (en) 2012-06-04
EP2453746A4 (en) 2013-04-24
SG177579A1 (en) 2012-02-28
US20120115909A1 (en) 2012-05-10
MX2012000768A (en) 2012-02-13
JP2012533564A (en) 2012-12-27
AU2010273261A1 (en) 2012-02-02
CA2768015C (en) 2016-03-15
US9062037B2 (en) 2015-06-23
EA022322B1 (en) 2015-12-30
CA2768015A1 (en) 2011-01-20
JP5635090B2 (en) 2014-12-03
CN102595892A (en) 2012-07-18
KR101536806B1 (en) 2015-07-14
NZ598240A (en) 2013-10-25
BR112012001680A2 (en) 2015-09-01
EP2453746A1 (en) 2012-05-23
ZA201200253B (en) 2013-05-29
EA201270176A1 (en) 2012-08-30
WO2011009023A1 (en) 2011-01-20
AU2010273261B2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
JO3199B1 (en) Substituted 5-fluoro-1H-pyrazolopyridines and their use
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
MY169980A (en) Bisaryl-linked aryltriazolones and their use
PH12013501143A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
MX2013008850A (en) Compositions and methods for treating cardiovascular diseases.
MX2012003770A (en) Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products.
PH12012501838A1 (en) Aptamers to ãŸ-ngf and their use in treating ãŸ-ngf mediated diseases and disorders
IN2014DN09434A (en)
MX2020009780A (en) Autotaxin inhibitor compounds.
AU2011328009A8 (en) Compounds and methods for treating pain
NZ702977A (en) 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
MX2021007268A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
EA201600096A1 (en) BENZYL-1H-PYRAZOL [3,4-B] Pyridine and their use
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
IL216967A0 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
WO2014015056A3 (en) Anti-mucus drugs and uses therefor
PH12012501389A1 (en) Hedgehog inhibitors
UA86731C2 (en) Divisible galenic form of the modified drug release
IN2014MN01542A (en)
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.
MX363549B (en) Antidiabetic solid pharmaceutical compositions.
MX2012000768A (en) DERIVATIVES OF TAZAROTENE.
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.